Fraxin

Pharmacology & Research

Fraxin is a coumarin glucoside — fraxetin 8-O-glucoside — and one of the minor coumarins of horse-chestnut and ash bark, grouped with esculin as the seed’s coumarin fraction. Two framing points. It is the benign co-coumarin: unlike esculin, it does not carry horse chestnut’s “toxic component removed during standardisation” story, and it is a 7,8-dihydroxy/6-methoxy coumarin (via its aglycone fraxetin), not a 4-hydroxycoumarin — so, as with scopoletin, no warfarin-type anticoagulant claim applies. Its research is entirely preclinical and, as a glucoside, much of the in-vivo activity is plausibly its aglycone fraxetin’s.

1. Anti-inflammatory

Fraxin’s most reproduced signal is NF-κB restraint across acute injury models: LPS-induced acute lung injury via NF-κB/NLRP3 ^{2Reference 22019Fraxin ameliorates lipopolysaccharide-induced acute lung injury via NF-κB and NLRP3View study →}, ARDS with reduced pulmonary vascular permeability ^{3Reference 32019Fraxin alleviates LPS-induced ARDS by reducing inflammation, oxidative damage and pulmonary vascular permeabilityView study →}, ulcerative colitis via TLR4/NF-κB and MAPK ^{4Reference 42024Fraxin ameliorates ulcerative colitis by modulating oxidative stress, TLR4/NF-κB and MAPKView study →}, and cerebral ischemia-reperfusion via PPAR-γ/NF-κB ^{5Reference 52022Protective effects of fraxin on cerebral ischemia-reperfusion injury via the PPAR-γ/NF-κB pathwayView study →}.

Gap: all acute rodent/cell models, in single-lab clusters, with no human data and model-specific effect sizes ^{2,4Reference 22019Fraxin ameliorates lipopolysaccharide-induced acute lung injury via NF-κB and NLRP3View study →Reference 42024Fraxin ameliorates ulcerative colitis by modulating oxidative stress, TLR4/NF-κB and MAPKView study →}.

2. Hepatoprotective

Fraxin reduced CCl₄-induced hepatotoxicity in vitro and in vivo through hepatic antioxidant/anti-inflammatory action and MAPK-NF-κB regulation ^{6Reference 62017Hepatoprotective effect of fraxin against CCl₄-induced hepatotoxicity via MAPK-NF-κBView study →}, and protected against a second chemically-induced hepatotoxicity model by lowering oxidative stress ^{7Reference 72017Fraxin prevents chemically induced hepatotoxicity by reducing oxidative stressView study →}.

Gap: rodent/cell only, in the classic “reduce oxidative stress in a toxin model” design, with no clinical translation ^{6,7Reference 62017Hepatoprotective effect of fraxin against CCl₄-induced hepatotoxicity via MAPK-NF-κBView study →Reference 72017Fraxin prevents chemically induced hepatotoxicity by reducing oxidative stressView study →}.

3. Antioxidant / Nrf2

Fraxin and structurally related compounds protect cells from oxidative stress ^{8Reference 82005Natural compounds — fraxin and chemicals structurally related to fraxin — protect cells from oxidative stressView study →}, consistent with the coumarin scaffold’s Keap1/Nrf2/ARE modulation reviewed for the class ^{1Reference 12024ReviewPharmacological activities of plant-derived fraxin with molecular mechanisms: a comprehensive reviewView study →}.

Gap: foundational hydroxycoumarin radical-scavenging chemistry shared across the esculin/esculetin/fraxetin family — largely class-level, not fraxin-specific, with no in-vivo human antioxidant readout ^{1,8Reference 12024ReviewPharmacological activities of plant-derived fraxin with molecular mechanisms: a comprehensive reviewView study →Reference 82005Natural compounds — fraxin and chemicals structurally related to fraxin — protect cells from oxidative stressView study →}.

4. Bone protection

An emerging rodent cluster: fraxin delays glucocorticoid-induced osteoporosis via Nrf2/GPX4 (restraining ferroptosis) ^{9Reference 92024Fraxin targets ferroptosis via Nrf2/GPX4 in glucocorticoid-induced osteoporosisView study →} and prevents knee osteoarthritis by inhibiting chondrocyte apoptosis ^{10Reference 102021Fraxin prevents knee osteoarthritis through inhibiting chondrocyte apoptosisView study →}.

Gap: the newest and least replicated theme, entirely preclinical ^{9,10Reference 92024Fraxin targets ferroptosis via Nrf2/GPX4 in glucocorticoid-induced osteoporosisView study →Reference 102021Fraxin prevents knee osteoarthritis through inhibiting chondrocyte apoptosisView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
NF-κB	suppressed activation	anti-inflammatory, hepatoprotective
NLRP3 inflammasome; TLR4 / MAPK	suppressed; downregulated	acute lung injury, colitis
PPAR-γ	activated (anti-inflammatory)	cerebral ischemia-reperfusion
Nrf2 / GPX4 / ARE	activated; restrains ferroptosis	antioxidant, bone
ROS / oxidative stress	direct scavenging + lowered	hepato/bone/antioxidant

All mechanisms are preclinical (rodent/cell).

Pharmacokinetics

Fraxin is a coumarin O-glucoside, so it is expected to be poorly absorbed intact and hydrolysed to its aglycone fraxetin by gut/microbial β-glucosidases — the same pattern as esculin→esculetin. A UPLC-MS/MS study in beagle dogs given a Ledum palustre extract measured fraxin alongside fraxetin (and aesculin/aesculetin) in plasma, consistent with glucoside/aglycone interconversion in vivo ^{12Reference 122018Simultaneous determination of aesculin, aesculetin, fraxetin, fraxin and polydatin in beagle-dog plasma by UPLC-ESI-MS/MS after oral extractView study →}. No dedicated single-isolate human pharmacokinetics exists, and much of the reported in-vivo bioactivity is plausibly mediated by fraxetin.

Clinical trials

There are no human clinical trials of isolated fraxin. Human use is only as an untargeted minor constituent of Cortex Fraxini/horse-chestnut preparations, where activity belongs to the whole extract, not to fraxin.

Last checked: July 2026.

Toxicity & Safety

Fraxin is a minor dietary/medicinal coumarin glucoside with low apparent toxicity — no isolated-toxicity signal appears in the reviewed literature ^{1Reference 12024ReviewPharmacological activities of plant-derived fraxin with molecular mechanisms: a comprehensive reviewView study →}, and in the injury models it is uniformly protective rather than toxic. Two discipline points: it should not inherit esculin’s [moderate] “toxic component removed during standardisation” framing (that is esculin-specific; fraxin is the benign co-coumarin), and it is not a warfarin-type anticoagulant — a 7,8-dihydroxy/6-methoxy coumarin via fraxetin, not a 4-hydroxycoumarin, so the “coumarins thin the blood” claim does not apply and any coumarin-bleeding caution is theoretical. Note also that the classic Cortex Fraxini anti-gout/uricosuric use rests on the whole coumarin fraction, not isolated fraxin ^{11Reference 112011AnimalProtective effects of Cortex Fraxini coumarines against oxonate-induced hyperuricemia and renal dysfunction in mice (whole coumarin fraction, not isolated fraxin)View study →} — so fraxin itself should not be claimed uricosuric.

Pregnancy & lactation

Avoid. There are no reproductive-safety data on isolated fraxin; the standard caution for an unstudied coumarin glycoside applies. It is not an anticoagulant, so there is no warfarin-class fetal concern, but the absence of data governs.

Dosage

There is no established human dose — fraxin has never been administered to humans as an isolate. All figures in the literature are preclinical research doses (rodent, mg/kg) and are not a recommendation.

References